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E-mail address: zyousyou8@yahoo.co.jp (M. YoshiA link between cellular uptake of high density lipoprotein (HDL) and regulation of sterol regulatory
element-binding protein-1 (SREBP-1) was investigated in vitro. HDL decreased nuclear SREBP-1 lev-
els as well as SREBP-1 target gene expression in HepG2 and HEK293 cells. However, HDL did not
repress an exogenously expressed, constitutively active form of SREBP-1. HDL increased cellular cho-
lesterol levels, and cellular cholesterol depletion by methyl-b-cyclodextrin abolished the effects of
HDL. These results suggest that HDL inhibits the activation of SREBP-1 through a cholesterol-depen-
dent mechanism, which may play an important role in regulating lipid synthetic pathways mediated
by SREBP-1.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
High density lipoprotein (HDL) protects against atherosclerosis
[1] through reverse cholesterol transport (RCT). During RCT, HDL
receives cellular cholesterol from peripheral tissues and transports
its lipid cargo to the liver and other tissues [2]. Low serum HDL-
cholesterol (HDL-c) also correlates with other metabolic disorders
such as non-alcoholic fatty liver disease (NAFLD) and obesity [3,4],
although a causal link has not been established. Cellular uptake of
HDL-c occurs through a number of mechanisms, including via
scavenger receptor class BI (SRBI)-mediated pathways [5]. RCT
changes the cellular cholesterol pool and leads to enhanced cellular
cholesterol utilization [6] and broad inﬂuences on cell function
[7].chemical Societies. Published by E
(-cholesterol); RCT, reverse
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binding protein-1; nSREBP-1
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glyceraldehyde-3-phosphate
da).Sterol regulatory element-binding protein (SREBP) is a basic he-
lix–loop–helix leucine zipper transcription factor and sensitive to
cellular cholesterol. SREBP is found in three isoforms; SREBP-1a,
1c and SREBP-2, and is ubiquitously expressed in human andmouse
tissues, but at higher levels in liver [8]. Normally, SREBP localizes to
the endoplasmic reticulum (ER) membrane as a complex with
SREBP cleavage activating protein (SCAP), which is further bound
to insulin-induced gene (Insig). A reduction in cellular cholesterol
sequentially leads to release of the SREBP-SCAP complex from Insig
and translocation to the Golgi apparatus, where SREBP gets cleaved
at its N-terminus by site 1 and site 2 proteases. Cleaved (active)
SREBP translocates to the nucleus where SREBP-1 upregulates the
expression of lipogenic enzymeswhereas SREBP-2 upregulates cho-
lesterol biosynthetic genes [7]. Excessive activation of SREBP-1 in-
duces abnormal lipid synthesis as well as cellular lipotoxicity,
contributing tometabolic disorders such as fatty liver disease, insu-
lin resistance, diabetes and cardiovascular disease [9]. Thus SREBP-
1 may be an important target to combat metabolic disorders
accompanied by abnormal lipid accumulation in cells.
Although SREBP-2 is known to be regulated by intracellular and
extracellular cholesterol including HDL-c [7], the effects of HDL on
SREBP-1 are less well understood. In this study, we focused on
the effects of HDL on SREBP-1 and showed that HDL inhibited
activation of SREBP-1 in HepG2 and HEK293 cells, suggesting a no-
vel pathway involving HDL and SREBP-1.lsevier B.V. All rights reserved.
Fig. 1. HDL reduces nSREBP-1 in HepG2 and HEK293 cells. (A) Effects of MG132
(10 lM) and HDL on endogenous pSREBP-1 and nSREBP-1 levels in HepG2 cells.
Endogenous SREBP-1 was detected by anti-SREBP-1 monoclonal antibody (2A4).
Lamin A and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as
markers of nuclear and cytosolic fractions, respectively. (B) pSREBP-1 and nSREBP-1
levels in (A) were represented as band intensity (band density  area) relative to
0 mg/dl HDL-c. N = 3, *P < 0.05 vs 0 mg/dl HDL-c. (C) Effect of HDL-c concentration
on endogenous SREBP-1 proteins in HepG2 cells. (D) Effect of HDL on endogenous
nSREBP-1 and pSREBP-1 levels in HEK293 cells. (E) Effect of HDL-c concentration on
exogenous SREBP-1 levels (in total cell lysates) in BP-1a-full(FM)-transfected
HEK293 cells. Exogenous SREBP-1 was detected by anti-Flag M2 antibody. (F) Effect
of HDL on exogenous nSREBP-1 levels in empty vector (), BP-1a-full(FM) or BP-1a-
490(F)-transfected HEK293 cells.
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2.1. Preparation of HDL
Plasma HDL (d = 1.063–1.21) was isolated from the pooled plas-
ma of male SD rats (SLC Japan) or healthy volunteers using stan-
dard discontinuous density gradient ultracentrifugation [10] and
checked by Coomassie Brilliant Blue (CBB) staining following
SDS–PAGE. HDL-c concentration was determined by using a com-
mercial kit (Wako, Osaka, Japan).
2.2. Cell culture and treatment with HDL
HepG2 (human hepatoma) and HEK293 (human embryonic kid-
ney) cells were maintained in DMEM containing 5.5 mM glucose,
10% fetal bovine serum, 100 units/ml penicillin, 100 lg/ml strepto-
mycin, 37 C, humidiﬁed, 95% air and 5% CO2. For HDL treatment,
cells (70–80% conﬂuent) were incubated in serum-free DMEM for
12 h then treated with HDL (in serum-free medium) for 18 h. In
experiments looking at nuclear SREBP-1, DMSO (vehicle) or
10 lM MG132 were added to cells 2 h before sample preparation.
Methyl-b-cyclodextrin (MbCD, 0.5%) or Glyburide (Gly, 0.5 mM)
were also added to cells 2 h before sample preparation.
2.3. Measurement of intracellular free cholesterol/cholesterol ester
The total and free cholesterol levels were measured using the
method described by Gamble et al. [11]. In brief, control or HDL-
treated cells were collected and washed twice with PBS. Cellular
lipids were extracted by chloroform–methanol (2:1), and then son-
icated. After the centrifugation, lipid phase was evaporated under
N2 gas and dissolved in 2-propanol containing 10% Triton X-100.
Total and free cholesterol levels were determined by using a com-
mercial kit (Wako) and normalized by total cell protein. Choleste-
ryl ester levels were calculated using total cholesterol minus free
cholesterol.
2.4. Plasmid constructs
Construction of protein expression plasmids encoding full-
length human SREBP-1a with an N-terminal Flag and C-terminal
myc tag [BP-1a-full(FM)] and a truncated human SREBP-1a con-
taining residues 1–490 with an N-terminal Flag tag [BP-1a-
490(F)] is described in the Supplementary data. The pGL3-basic
luciferase reporter vector containing the rat fatty acid synthase
(FAS) promoter [pGL-FAS(-444)] and b-galactosidase expression
vector (pCMV-b) were previously reported [12].
2.5. Transfection and luciferase assays
HepG2 and HEK293 cells were transfected with Lipofect-
amine™ 2000 (Invitrogen) or PolyFect (QIAGEN) as recommended
by the manufacturer. For HDL treatments, cells were starved as
shown above 24 h after the transfection and then treated with
HDL. Luciferase reporter assays were performed with the luciferase
assay system (Promega) as previously reported [13].
2.6. Protein extraction and immunoblotting
Preparation of nuclear, cytosolic and total cell lysates, SDS–
PAGE (with 8% gels and 20–60 lg proteins) and immunoblotting
were performed as previously reported [13,14]. The antibodies
used for immunoblotting are detailed in the Supplementary data.
Endogenous or exogenous SREBP-1 was detected by anti-SREBP-1
monoclonal antibody (2A4) or by anti-Flag M2 antibody.2.7. RNA extraction and real-time RT-PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) and re-
verse transcribed using TaKaRa PrimeScript RT reagent (TaKaRa).
Quantitative real-time PCR was performed with the LightCycler
system (Roche Diagnostics) using TaKaRa SYBR Premix Ex Taq
(TaKaRa). The primers used in this study are detailed in the Supple-
mentary data.
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All results are presented as means ± S.D. Statistical signiﬁcance
was determined using Student’s t-test. The threshold for signiﬁ-Fig. 2. MbCD, but not Glyburide, prevents the repression of nSREBP-1 by HDL. (A)
Effects of HDL, methyl-b-cyclodextrin (MbCD, 0.5%) or Glyburide (Gly, 0.5 mM) on
endogenous nSREBP-1 levels in HepG2 cells. (B) Protein levels of nSREBP-1 in (A)
were represented as band intensity (band density  area) relative to 0 mg/dl HDL-c.
N = 3, *P < 0.05 vs 0 mg/dl HDL-c.
Fig. 3. HDL increases cellular cholesterol levels, but MbCD reverses the effect of HDL. (A) E
N = 4, *P < 0.05 vs 0 mg/dl HDL-c without ()MbCD, P < 0.05 vs without ()MbCD and P <
in HEK293 cells. N = 5, *P < 0.05 vs 0 mg/dl HDL-c.cance was set at P < 0.05, and each experiment was repeated at
least three times.
3. Results
In this study, HDL isolated from rats or humans (hereafter re-
ferred to as ‘‘HDL” or ‘‘human HDL”, respectively) was used to ana-
lyze the effects of HDL on SREBP-1.
First, we conﬁrmed the levels of precursor, full-length SREBP-1
(pSREBP-1) (cytosolic protein fractions) and active, nuclear SREBP-
1 (nSREBP-1) (nuclear protein fractions) in HepG2 and HEK293
cells incubated in either the absence or the presence of 50 mg/dl
HDL-c. Because nSREBP-1 is rapidly degraded by the Ubiquitin-
26S proteasome [15], cells were treated with the Ubiquitin-protea-
some inhibitor MG132 (10 lM), which increased detectable
nSREBP-1 compared with vehicle (DMSO)-treated cells (Fig. 1A,
lanes 1 and 2). Thus hereafter, MG132 was used in the experiments
to detect SREBP-1 proteins. HDL signiﬁcantly decreased nSREBP-1
levels in the presence of MG132, and concomitantly increased
pSREBP-1 levels (Fig. 1A, lane 3 and 1B). This effect of HDL was
dose-dependent between 5 and 50 mg/dl HDL-c (Fig. 1C). HDL also
decreased endogenous nSREBP-1 and increased pSREBP-1 levels in
HEK-293 cells (Fig. 1D). When SREBP-1 was overexpressed by
transfection with the BP-1a-full(FM) plasmid (see Section 2), HDL
reduced the exogenous nSREBP-1 levels (Fig. 1E and F, lane 2).
However, this effect was not evident below 50 mg/dl HDL-c, prob-
ably due to the increased levels of SREBP-1 (Fig. 1E). Overexpres-
sion of a truncated form of SREBP-1, using the BP-1a-490(F)
plasmid, resulted in constitutive nuclear translocation of SREBP-1ffect of HDL on cellular cholesterol levels in HepG2 cells with/without MbCD (0.5%).
0.05 vs 0 mg/dl HDL-c with (+)MbCD. (B) Effect of HDL on cellular cholesterol levels
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lane3).
To further investigate the mechanisms by which HDL decreased
nSREBP-1 levels, we tested the roles of cellular cholesterol and SRBI
(Fig. 2). Treatment with the cholesterol depleting agent, methyl-b-
cyclodextrin (MbCD; 0.5%) abolished the effect of HDL (Fig. 2A, lane
2 and Fig. 2B), whereas the SRBI inhibitor, Glyburide (0.5 mM) [23]
had little effect on the HDL-mediated reduction of nSREBP-1
(Fig. 2A lane 3 and Fig. 2B).
Because the effect of HDL was abolished by depletion of cellular
cholesterol, we next quantiﬁed cellular cholesterol levels in HepG2
and HEK293 cells incubated in the absence or the presence of
50 mg/dl HDL-c (Fig. 3). HDL signiﬁcantly increased cellular choles-
terol levels, in particular free cholesterol (FC) levels but not cho-
lesteryl ester (CE) levels in HepG2 and HEK293 cells (Fig. 3A and
B). Treatment with MbCD decreased basal cholesterol levels in
HepG2 cells (Fig. 3A, open square), and the HDL-induced increase
in cellular cholesterol levels was also reversed by MbCD (Fig. 3A,
closed square). Because MbCD dramatically decreased the viability
of HEK293 cells regardless of HDL treatment, HEK293 cells were
not used in MbCD assay (data not shown).
We also looked at the effect of HDL on SREBP-1 target genes by
luciferase assay and by real time RT-PCR. HDL reduced FAS pro-
moter activity in HepG2 and HEK293 cells (Fig. 4A and B, No. 1).
Transfection with BP-1a-full(FM) increased FAS promoter activity
and this effect was also attenuated by HDL (Fig. 4B, No. 2), whereas
increased FAS promoter activation by transfection with BP-1a-
490(F) was not changed by HDL (Fig. 4, No. 3). Expression levels
of SREBP-1 target genes such as Fatty acid synthase (FAS), Acetyl-
coA carboxylase (ACC), Stearyl-coA desaturase (SCD1), as well asFig. 4. HDL reduces FAS promoter activity in HepG2 and HEK293 cells. (A) Effect of
HDL on luciferase activity in HepG2 cells transfected with FAS promoter-luciferase
(pGL-FAS(-444)) and b-galactosidase (pCMV-b) plasmids. Luciferase activity was
normalized to b-galactosidase and was relative to 0 mg/dl HDL-c. N = 4, *P < 0.05 vs
0 mg/dl HDL-c. (B) Effect of HDL on luciferase activity in HEK293 cells transfected
with/without BP-1a-full(FM) or BP-1a-490(F) in addition to pGL-FAS(-444) and
pCMV-b. Luciferase activity was normalized to b-galactosidase and was relative to
both without ()BP-1a-full(FM) and without ()BP-1a-490(F). N = 4, *P < 0.05 vs
0 mg/dl HDL-c.
Fig. 5. HDL represses mRNA levels of lipogenic genes in (A) HepG2 and (B) HEK293
cells. Total RNA isolated from cells treated with/without HDL for 18 h was analyzed
by real-time RT-PCR. Gene expression was normalized to GAPDH and was relative
to 0 mg/dl HDL-c. N = 4, *P < 0.05 vs 0 mg/dl HDL-c.SREBP-1 (SREBP-1a and 1c) itself were reduced in HDL-treated
HepG2 and HEK293 cells (Fig. 5A and B).
Finally, we conﬁrmed the effect of human HDL on the activation
of SREBP-1. Human HDL decreased endogenous nSREBP-1 levels
and increased pSREBP-1 levels in HepG2 and HEK293 cells
(Fig. 6A and B), although this effect appeared to be smaller than
that of HDL isolated from rats (Fig. 1A and D). SREBP-1a, SREBP-
1c and FAS gene were differentially expressed between HepG2
and HEK293 cells (Fig. 6C, open square), and the expression levels
of these genes were reduced in both HDL-treated HepG2 and
HEK293 cells. However, the reduction rates were different between
both the cells and the genes (Fig. 6C, closed square).
4. Discussion
Although cellular cholesterol homeostasis can be regulated by
HDL via SREBP-2 pathways [16], the effect of HDL on cellular lipid
metabolism is unclear. In this study, we showed that HDL inhibits
the activation of SREBP-1 and decreases the expression levels of
SREBP-1 target genes in cultured cells. These results suggest a no-
vel role for HDL in the regulation of cellular lipid synthesis.
HDL decreased nSREBP-1 levels, probably by inhibiting the
cleavage or translocation steps (from ER to Golgi) of SREBP-1 be-
cause (1) HDL decreased nSREBP-1 levels even in the presence of
the Ubiquitin-proteasome inhibitor MG132 and (2) HDL also de-
creased exogenous (BP-1a-full(FM)) full-length SREBP-1 but not a
constitutively active (truncated) form (BP-1a-490(F)). These results
reﬂect increased levels of pSREBP-1 as well as FAS promoter
Fig. 6. Human HDL also inhibits the activation of SREBP-1. Effect of HDL isolated
from humans on endogenous nSREBP-1 and pSREBP-1 levels in (A) HepG2 and (B)
HEK293 cells. (C) Total RNA isolated from cells treated with/without human HDL for
18 h was analyzed by real-time RT-PCR. Gene expression was normalized to GAPDH
and was relative to HepG2 cells with 0 mg/dl HDL-c. N = 4, *P < 0.05 vs 0 mg/dl
HDL-c.
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out the involvement of nSREBP-1-degrading pathways.
SREBP-1 is processed by either cholesterol-dependent or -inde-
pendent mechanisms. SREBP-1a can be regulated via the sterol-
sensing machinery mediated by SCAP [7] whereas SREBP-1c is
not sensitive to cellular cholesterol but instead regulated by stim-
uli such as insulin [17]. However, HDL indeed decreased nSREBP-1
with increased levels of cellular cholesterol, and depletion of cellu-
lar cholesterol by MbCD abolished the effect of HDL, suggesting
that increased levels of cellular cholesterol are involved in the
HDL-mediated inhibition of SREBP-1. Although normal cholesterol
levels were different between HepG2 (approximately 65 ng/lg
protein) and HEK293 cells (approximately 5 ng/lg protein), HDL-
induced increase in cellular cholesterol levels was approximately
5–10 ng/lg protein, which was enough to inhibit SREBP-1 in both
HepG2 and HEK293 cells. And the pathway by which HDL increases
cellular FC levels may be effective in the inhibition of SREBP-1,
whereas HDL-CE needs to be hydrolyzed to enter cellular choles-
terol utilization pathways [18]. However, we note that a signiﬁcant
increase in cellular cholesterol levels was also observed in HDL-
treated HepG2 cells incubated in MbCD (+HDL+MbCD cells) com-
pared with HDL+MbCD cells, as well as a signiﬁcant difference
between HDLMbCD and +HDLMbCD cells. The absolute values
of cellular cholesterol levels were lower in both HDL+MbCD and
+HDL+MbCD cells than that in HDLMbCD (normal) cells. Thus
SREBP-1 is inhibited by HDL when the HDL-induced increase in
cellular cholesterol levels exceeds the basal cholesterol levels ob-
served in normal cells. However, we cannot rule out the implica-
tion of an unknown mechanism by which HDL increased cellularcholesterol levels regardless of MbCD treatment. On the other
hand, Gharavi et al. reported that oxidized-phospholipid (named
Ox-PAPC) sequentially induced depletion of caveolar (lipid-rich
cellular membrane) cholesterol and nSREBP-1 formation in human
aortic endothelial cells, whereas HDL prevented the Ox-PAPC-in-
duced nSREBP-1 formation, possibly through the maintenance of
the membrane cholesterol [19]. Although the precise mechanism
in the previous study was unclear, the difference of cellular choles-
terol levels between HDL+MbCD and +HDL+MbCD cells may be
explained by the protective effect of HDL against cholesterol deple-
tion by MbCD. And if so, HDL-mediated modiﬁcation of the cellular
membrane is considered to be important for regulating SREBP-1.
We also note that both SREBP-1a and -1c are dependent on SCAP
for their N-terminal cleavage regardless of cellular cholesterol
[20], and SCAP overexpression makes SREBP activation insensitive
to cholesterol levels [21]. Thus, the use of cells overexpressing
SCAP will be a valuable tool for elucidating the mechanism of the
HDL action. However, the method is likely to affect all activation
pathways of SREBP-1 and may complicate our understanding. Fur-
ther studies are needed to elucidate the possible mechanism of the
HDL action.
Many proteins have been identiﬁed as HDL-binding proteins,
some of which enhance cellular uptake of HDL [2]. Especially,
HDL receptor SRBI plays a central role in receptor-mediated inﬂux
pathways of HDL-c [5]. However, SRBI did not appear to be re-
quired for the HDL-mediated inhibition of SREBP-1 because HDL
also decreased nSREBP-1 in HEK-293 cells in which SRBI is not ex-
pressed [22,23]. Similarly, the effect of HDL was not affected by the
SRBI inhibitor, Glyburide. Although Glyburide is commonly used to
inhibit ATP binding cassette (ABC) superfamily such as ABCA1, Gly-
buride also inhibits SRBI activity to the same extent as more spe-
ciﬁc inhibitors, block lipid transport molecules (BLTs) [24].
Furthermore, MbCD has been reported to enhance the SRBI-medi-
ated inﬂux of HDL-CE in HepG2 cells [25], whereas MbCD abol-
ished the effect of HDL in our study. Thus we concluded that, at
least in part, SRBI-independent factors are involved in the effect
of HDL. However, we also note that SRBI knock out mice reported
in a recent study exhibited a 2.54-fold increase in SREBP-1 mRNA
levels [26]. Thus further studies are needed to conﬁrm the involve-
ment of SRBI both in vitro and in vivo. Lipid lipases such as hepatic
lipase (HL), lipoprotein lipase (LPL) and endothelial lipase (EL) also
enhance cellular uptake of HDL by interacting with cell surface
proteoglycans, and the pathways are independent of SRBI
[22,23,27]. However, removal of lipid lipases with heparin
(100 U/ml) [28,29] had no effect on the HDL-mediated inhibition
of SREBP-1 (Supplementary ﬁgure). Other proteins including apoB
receptors, apoE receptors, cubilin and megalin are also involved in
the cellular uptake of HDL [2], and they will be further addressed in
future studies.
Consistent with the reduction of nSREBP-1 levels, expression
levels of SREBP-1 target genes and SREBP-1 itself were decreased
in HDL-treated HepG2 and HEK293 cells. Although cellular treat-
ment with HDL for 18 h (and 36 h, data not shown) decreased
nSREBP-1 and increased pSREBP-1, longer-term treatment with
HDL is likely to decrease both nSREBP-1 and pSREBP-1 levels, pre-
sumably because of decreased mRNA levels of SREBP-1. S1P-deﬁ-
cient mice, in which the activation of SREBP-1 is hampered by
the inability of cleavage at site 1, may be a predictive model for this
hypothesis. These mice exhibit considerably lower expression of
SREBP-1 at both protein and mRNA levels, although expression lev-
els of SCAP as well as its response to the cellular cholesterol are
normal [30]. Thus both actions of HDL, the reduction of both
nSREBP-1 and SREBP-1 (mRNA and protein) expression, may play
an important role in lipid synthetic pathways in vivo. And impor-
tantly, HDL isolated from humans also inhibited the activation of
SREBP-1. In humans, but not in rodents, cholesteryl ester transfer
1222 M. Yoshida et al. / FEBS Letters 584 (2010) 1217–1222protein (CETP) mediates the transfer of cholesteryl esters from HDL
to other lipoproteins [2], suggesting that the mechanism by which
HDL inhibits SREBP-1 is more diverse in humans than that in ro-
dents. And the diversity is considered to change the efﬁciency of
the HDL actions. To exclude the bias of exogenous CETP proteins,
HDL isolated from rats lacking CETP [2] was used in our experi-
ments. However, our results will provide a basis for understanding
the link between HDL and SREBP-1 in humans.
In summary, HDL inhibits the activation of SREBP-1 and de-
creased the expression levels of SREBP-1 target genes, probably
by increasing levels of cellular cholesterol. These ﬁndings raise
the possibility that circulating HDL links to the lipid synthetic
pathway, and the maintenance of serum HDL-c levels may be
important for the prevention of abnormal lipid synthesis as well
as cardiovascular diseases.
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